Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osimertinib - AstraZeneca

Drug Profile

Osimertinib - AstraZeneca

Alternative Names: [11C]AZD9291; [11C]osimertinib; AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 02 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly and Company; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Princess Margaret Hospital (University of Toronto); Singapore Clinical Research Institute; Sunnybrook Health Sciences Centre; University of California at San Francisco
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Glioblastoma; Meningeal carcinomatosis
  • Phase I Solid tumours

Most Recent Events

  • 26 Feb 2020 AstraZeneca completes the phase III FLAURA trial in Non-small cell lung cancer (Late stage disease, First-line therapy) in USA, Canada, United Kingdom, Hungary, Italy, Germany, Romania, France, Spain, Belgium, Czech Republic, Bulgaria, Poland, Switzerland, Russia, Ukraine, Thailand, Taiwan, Philippines, South Korea, Japan, Turkey, Australia, Brazil, China, Israel, Malaysia, Portugal, Saudi Arabia, Sweden and Vietnam (NCT02296125) (AstraZeneca pipeline, February 2020)
  • 26 Feb 2020 AstraZeneca terminates a phase Ib/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Taiwan and South Korea due to strategic reasons (NCT03381274) (AstraZeneca pipeline, February 2020)
  • 26 Feb 2020 Jonsson Comprehensive Cancer Center in collaboration with National Cancer Institute, Eli Lilly and Genentech plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US (PO)(NCT04285671)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AskTheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top